Stock analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Talphera in a research note issued on ...

Stock analysts at HC Wainwright boosted their Q2 2025 EPS estimates for Perspective Therapeutics in a research note issued on ...

H.C. Wainwright sees increased uncertainty for Sarepta’s Elevidys franchise after the European Medicines Agency placed a clinical hold on three drug trials. The clinical hold on ...

H.C. Wainwright lowered the firm’s price target on Galaxy Digital (BRPHF) to C$30 from C$35 and kept a Buy rating on the shares ...

Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...

Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

Knightscope, Inc. (NASDAQ: KSCP), a leader in developing autonomous security robots and artificial intelligence technologies, closed on the previously announced sale of an aggregate of 625,000 shares ...

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.

On Monday, H.C. Wainwright reaffirmed its Buy rating and $6.00 price target for Veritone (NASDAQ:VERI), a $116 million market cap company currently trading at $2.61, following the company’s ...

On Monday, H.C. Wainwright reaffirmed a positive stance on Candel Therapeutics Inc. (NASDAQ:CADL), maintaining its Buy rating and a $19.00 price target. Trading at $8.75 with a market ...